Search

Background: WNT signaling plays a key role in postnatal bone formation. Individuals with gain-of-function mutations in the WNT co-receptor LRP5 exhibit increased lower-body fat mass and potentially enhanced glucose metabolism, alongside high bone mass. However, the mechanisms by which LRP5 regulates fat distribution and its effects on systemic metabolism remain unclear. This study aims to explore the role of LRP5 in adipose tissue biology and its impact on metabolism., Methods: Metabolic assessments and imaging were conducted on individuals with gain- and loss-of-function LRP5 mutations, along with age- and BMI-matched controls. Mendelian randomization analyses were used to investigate the relationship between bone, fat distribution, and systemic metabolism. Functional studies and RNA sequencing were performed on abdominal and gluteal adipose cells with LRP5 knockdown., Results: Here we show that LRP5 promotes lower-body fat distribution and enhances systemic and adipocyte insulin sensitivity through cell-autonomous mechanisms, independent of its bone-related functions. LRP5 supports adipose progenitor cell function by activating WNT/β-catenin signaling and preserving valosin-containing protein (VCP)-mediated proteostasis. LRP5 expression in adipose progenitors declines with age, but gain-of-function LRP5 variants protect against age-related fat loss in the lower body., Conclusions: Our findings underscore the critical role of LRP5 in regulating lower-body fat distribution and insulin sensitivity, independent of its effects on bone. Pharmacological activation of LRP5 in adipose tissue may offer a promising strategy to prevent age-related fat redistribution and metabolic disorders., Competing Interests: Competing interests: The authors declare the following competing interests: C.C. and F.K. have received research funding from Novo Nordisk and Takeda. M.V. and A.D.vD were supported by Novo Nordisk Postdoctoral Research Fellowships. The funders had no role in the study design, analysis or reporting of the current work. M.V. is an employee of Novo Nordisk Ltd., UK (Novo Nordisk Research Centre, Oxford). N.Y.L., S.K.V., D.B.R., E.R., D.P., A.W-A., M.J.N., R.N., D.W.R., J.H.T. and C.L.G. declare no competing interests., (© 2025. The Author(s).)